ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 64 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,322,097 | -23.4% | 464,812 | -31.2% | 0.00% | -100.0% |
Q2 2023 | $6,945,024 | +35713.9% | 675,586 | +26794.3% | 0.00% | – |
Q1 2023 | $19,392 | +288.0% | 2,512 | +269.4% | 0.00% | – |
Q4 2022 | $4,998 | +399.8% | 680 | +236.6% | 0.00% | – |
Q3 2022 | $1,000 | 0.0% | 202 | +50.7% | 0.00% | – |
Q2 2022 | $1,000 | -50.0% | 134 | -49.6% | 0.00% | – |
Q1 2022 | $2,000 | – | 266 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |